https://www.selleckchem.com/products/cay10444.html
4% 62.5%, =0.019) than those in TACE-L group. Multivariate analyses revealed that the treatment option of TACE-L, main portal vein invasion and extrahepatic metastasis were the independent risk factors for OS, while TACE-L and extrahepatic metastasis were the independent risk factors for PFS. In subgroup analyses, a superior survival benefit was achieved with TACE-L-P in patients with extrahepatic metastasis or tumor number 3 but not in those with main portal vein invasion. The incidence and severity of AEs in TACE-L-P group were c
Like
Comment
Share
